Changeflow GovPing Pharma & Drug Safety UCL Microsphere Drug Combination Patent EP40450...
Routine Notice Added Final

UCL Microsphere Drug Combination Patent EP4045004A1

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4045004A1 for UCL Business Ltd, titled 'Microsphere-Drug Combination.' The patent covers therapeutic compounds including microsphere formulations for drug delivery, with applications in oncology treatment (A61P 35/00). The invention involves pharmaceutical compositions using IPC classifications A61K 9/00, A61K 9/16, A61K 47/34, and related polymer and materials science classifications. The patent is designated for all European states.

What changed

The EPO published patent application EP4045004A1 for a microsphere-drug combination invented by Richard Day of UCL Business Ltd. The patent covers therapeutic formulations using microsphere technology with pharmaceutical compositions, including polymer-based drug delivery systems (IPC: A61K 9/16, A61K 47/34). The application includes oncology therapeutic claims (A61P 35/00) and is designated for all European patent convention states.

For pharmaceutical manufacturers and drug developers, this patent represents potential freedom-to-operate considerations for microsphere-based drug delivery technologies. The broad designation across European states means the patent could affect product development strategies in multiple jurisdictions if the patent grants after examination.

What to do next

  1. Monitor patent register for grant/opposition proceedings
  2. Review designated states coverage for business relevance

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MICROSPHERE-DRUG COMBINATION

Publication EP4045004A1 Kind: A1 Apr 08, 2026

Applicants

UCL Business Ltd

Inventors

DAY, Richard

IPC Classifications

A61K 9/00 20060101AFI20260305BHEP A61K 9/16 20060101ALI20260305BHEP A61K 47/34 20170101ALI20260305BHEP A61K 47/36 20060101ALI20260305BHEP C08J 9/28 20060101ALI20260305BHEP A61L 27/56 20060101ALI20260305BHEP A61K 31/337 20060101ALI20260305BHEP A61P 35/00 20060101ALI20260305BHEP B01J 13/02 20060101ALI20260305BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4045004A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent publication Drug delivery technology Pharmaceutical formulations
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!